Juniper Pharmaceuticals Inc. (JNP) Posts Earnings Results, Beats Expectations By $0.17 EPS
Juniper Pharmaceuticals Inc. (NASDAQ:JNP) announced its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.17. Juniper Pharmaceuticals had a negative net margin of 5.81% and a negative return on equity of 6.39%. The firm earned $11.60 million during the quarter, compared to analyst estimates of $10.35 million.
Shares of Juniper Pharmaceuticals (NASDAQ:JNP) opened at 5.95 on Wednesday. Juniper Pharmaceuticals has a 12 month low of $4.30 and a 12 month high of $12.67. The company’s market capitalization is $64.52 million. The company’s 50-day moving average is $5.56 and its 200 day moving average is $6.52.
A number of analysts have recently commented on JNP shares. Zacks Investment Research lowered shares of Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, July 25th. Northland Securities lowered shares of Juniper Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 18th. HC Wainwright lowered shares of Juniper Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $6.75 price target for the company. in a research note on Friday, August 19th. TheStreet lowered shares of Juniper Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, September 12th. Finally, Roth Capital set a $16.50 price target on shares of Juniper Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, August 21st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $11.50.
In other news, insider Alicia Secor purchased 5,000 shares of the stock in a transaction dated Thursday, August 25th. The shares were acquired at an average cost of $5.75 per share, for a total transaction of $28,750.00. Following the acquisition, the insider now owns 5,000 shares of the company’s stock, valued at $28,750. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director James A. Geraghty purchased 7,000 shares of the stock in a transaction dated Tuesday, August 23rd. The stock was purchased at an average price of $5.96 per share, for a total transaction of $41,720.00. Following the completion of the acquisition, the director now directly owns 58,216 shares in the company, valued at approximately $346,967.36. The disclosure for this purchase can be found here. 11.60% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in JNP. Eagle Global Advisors LLC purchased a new stake in Juniper Pharmaceuticals during the second quarter worth $241,000. Bridgeway Capital Management Inc. boosted its stake in Juniper Pharmaceuticals by 27.0% in the second quarter. Bridgeway Capital Management Inc. now owns 180,200 shares of the specialty pharmaceutical company’s stock worth $1,263,000 after buying an additional 38,350 shares in the last quarter. BlackRock Fund Advisors boosted its stake in Juniper Pharmaceuticals by 14.8% in the second quarter. BlackRock Fund Advisors now owns 28,292 shares of the specialty pharmaceutical company’s stock worth $198,000 after buying an additional 3,639 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Juniper Pharmaceuticals by 0.6% in the second quarter. Vanguard Group Inc. now owns 435,627 shares of the specialty pharmaceutical company’s stock worth $3,054,000 after buying an additional 2,588 shares in the last quarter. Institutional investors and hedge funds own 33.81% of the company’s stock.
Juniper Pharmaceuticals Company Profile
Juniper Pharmaceuticals, Inc, formerly Columbia Laboratories, Inc, is a women’s health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women’s health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE.
Receive News & Stock Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.